Today's Highlights
Premium
Amgen and Regeneron Rallies. See Other Outperforming Picks
The talk of the town now is about the anti-LDL drugs Repatha developed by Amgen (AMGN) and Praluent developed by Sanofi and Regeneron (REGN) ; both are PCSK9 inhibitors, a new class of anti-lipemic dr...
P
Prohost Biotech
1 min read
5
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Tags
Alnylam Pharmaceuticals (ALNY)
Amgen (AMGN)
Ariad Pharmaceuticals (ARIA)
Array BioPharma (ARRY)
Bellicum Pharmaceuticals Inc (BLCM)
BioCryst Pharmaceuticals (BCRX)
Celldex Therapeutics (CLDX)
Chimerix Inc (CMRX)
Compugen (CGEN)
Halozyme Therapeutics (HALO)
Illumina (ILMN)
Incyte (INCY)
Ionis Pharmaceuticals Inc (IONS)
Jazz Pharmaceuticals (JAZZ)
Juno Therapeutics (JUNO)
Nektar Therapeutics (NKTR)
Portola Pharmaceuticals Inc (PTLA)
PTC Therapeutics (PTCT)
Receptos Inc (RCPT)
Regeneron Pharmaceuticals (REGN)
Sanofi (SNY)
Seagen Inc (SGEN)
Sequenom (SQNM)
Tekmira Pharmaceuticals Corp (TKMR)
Theravance Biopharma (TBPH)
Theravance Inc (THRX)
Vertex Pharmaceuticals (VRTX)
Xoma (XOMA)
Comments (0)
Please sign in to join the discussion